cm-101
mAbexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 24, 2017 (NCT06025851)
Timeline
Indications
Mechanism of action
- C-C motif chemokine 24INHIBITOR
CCL24 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068577 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06210945 | Phase 2 | Sep 30, 2024 | ChemomAb Ltd. |
| NCT05824156 | Phase 2 | Feb 24, 2021 | ChemomAb Ltd. |
| NCT04595825 | Phase 2 | Oct 1, 2020 | ChemomAb Ltd. |
| NCT06037577 | Phase 1 | Mar 5, 2019 | ChemomAb Ltd. |
| NCT06044467 | Phase 1 | Dec 11, 2018 | ChemomAb Ltd., Hebrew University |
| NCT06025851 | Phase 1 | Jul 24, 2017 | ChemomAb Ltd., Tel Aviv University |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ChemomAb Ltd. | For profit | 6 | 6 | 2 | 2017 |
| Hebrew University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Tel Aviv University | Academic/Hospital | 1 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1